Psychedelic Neuroscience image

The FDA Just Authorized a Pioneering Experiment in Psychedelic Neuroscience

Share on facebook
Share on twitter
Share on linkedin
Share on email

Psychedelic biotechnology company Cybin Inc. announced on Tuesday that it has been granted Investigational New Drug authorization by the U.S. Food and Drug Administration to study the effects of ketamine on cerebral cortex hemodynamics.

While most results from psychedelic therapy and clinical trials rely on simple observation and patient self-reporting, Cybin’s previously announced partnership with neuroscience startup Kernel means that it can now utilize Kernel’s Flow headset to gather real-time quantitative data on neurological processes of psychedelic experiences.

“The word psychedelic means ‘mind-manifesting,’ but what has been missing is useful ‘mind-imaging’—the ability to dynamically trace the neural correlates of human conscious experience. Conventional neuroimaging just isn’t dynamic enough to study the psychedelic experience in the brain as it happens. This study of ketamine’s psychedelic effects while wearing headgear equipped with sensors to record brain activity could open up new frontiers of understanding,” said Dr. Alex Belser, Cybin’s Chief Clinical Officer in Tuesday’s press release. 

“Quantitatively measuring the brain within the context of a psychedelic experience is a promising frontier,” added Bryan Johnson, founder and Chief Executive Officer of Kernel. “With Kernel Flow, Cybin’s researchers can start putting numbers and quantification to subjective states of mind, including altered ones.” 

Ketamine, while technically a dissociative anesthetic, has the advantage of already being FDA approved for therapeutic use, as well as being more frequently employed in clinical settings in several forms. 

In 2016, the U.K.-based Beckley Foundation, in partnership with Imperial College London and psychedelic research luminary Robin Carhartt-Harris, made history with the first images of the brain on LSD, published in the paper ‘Neural correlates of the LSD experience revealed by multimodal neuroimaging’.

See Also
Microdose psychedelic capital conference graphic

While these results were achieved with a combination of conventional neuroimaging methods, including MEG and fMRI scans, accurate, cost-effective, and portable imaging and reporting of real-time neurological actions for psychedelic substances has the potential to significantly improve the quality and quantity of data collected by Cybin in its proprietary research. 

“We hope this feasibility study can bridge the gap of real-time quantitative data collection during psychedelic treatments to further understand the correlation of effects from these powerful molecules. The ability to access real-time brain activity data during a psychedelic experience has tremendous potential for the development of future psychedelic therapeutics,” stated Doug Drysdale, Chief Executive Officer of Cybin. 

DEA Again Boosts 2022 Production Goals For Psychedelics Like Psilocybin, MDMA and DMT: The final revised quotas "reflect DEA’s estimates of the medical, scientific, research, and industrial needs of the United States for 2022." https://www.marijuanamoment.net/dea-again-boosts-2022-production-goals-for-psychedelics-like-psilocybin-mdma-and-dmt/

BREAKING: MAPS and Vine Ventures announce creation of $70m SPV to fund patient access infrastructure and research for MDMA-assisted therapy for PTSD.

@MAPS, @VineVentures

What do we want the future of #psychedelic business to look like? We attended the Ethics in Psychedelics panel at this month's #PsyCap, hosted by @MicrodoseHQ, for some perspectives from @JasonNajum, @PaulaKahn2020 and K'uychi Florez.

Full article: http://ow.ly/SvI650H2ihq

"Psilocybin can treat depression, alcoholism, PTSD, and even cluster headaches. Why is it still illegal?"

Couldn't have said it better. Quality work from @thewalrus.

Full article: http://ow.ly/yQGc50H2a6O

#clusterheadaches #psilocybin #psilocybinheals

BREAKING: This morning,@jyduclos granted 2 more Canadians sec.56 exemptions so they may legally access #psilocybintherapy for end-of-life distress.

44 patients supported by TheraPsil now have exemptions.

Minister, THANK YOU.

Please continue to approve ALL in medical need.

Load More...

Related Articles

Scroll To Top